Scientists are rapidly examining retatrutide, a innovative drug developed by Eli Lilly, as a potential breakthrough in physique management. Different than many previous approaches, retatrutide is a dual -action receptor targeting both GLP-1 and GIP, hormones that impact satiety and blood sugar regu